Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

Bolsters Company’s Corporate Mission Financing Led by Board Member and Priced at Premium to Market Price WEXFORD, Pa., June 20, 2024 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce that it has closed on $4.3 million in a financing […]

June 20, 2024